Chagas disease, also known as American trypanosomiasis, is an infection caused by the protozoan flagellate *Trypanosoma cruzi,* which was discovered 104 years ago by the Brazilian physician [@B09]. The main mechanism of transmission of this infection to humans is vectorial via triatomine bugs, but other routes of infection are possible, such as blood transfusion, organ transplantation, laboratory accidents and transplacental and oral routes ([@B15]). Historically, Chagas disease has been considered endemic mainly in Latin America, where 10 million chronically infected individuals are distributed throughout 21 countries ([@B50]). The epidemiology of Chagas disease has changed significantly in recent decades as a consequence of urbanisation and population movement, particularly migration ([@B39]).

Chagas disease features an initial acute phase characterised by high levels of parasitaemia, but is generally asymptomatic or oligosymptomatic and rarely severe or lethal. The majority of chronically infected patients remain in the indeterminate clinical stage of the disease and approximately 30-40% of patients develop cardiac or gastrointestinal alterations ([@B36]). The chronic phase of the disease is characterised by a low level of parasitaemia and the presence of anti-*T. cruzi* IgG antibodies.

To date, only two drugs have been demonstrated to be effective for Chagas disease chemotherapy: nifurtimox, a nitrofuran derivative manufactured by Bayer as Lampit^(r)^, and benznidazole, a nitroimidazole derivative previously manufactured by Roche as Rochagan^(r)^ or Rodanil^(r)^ and now manufactured by Laboratório Farmacêutico do Estado de Pernambuco in Brazil and as Abarax^(r)^ by Laboratorio ELEA in Argentina. Both drugs may cause considerable side effects in some patients, particularly in older patients. In addition, these drugs are not recommended for pregnant women and patients with renal and hepatic dysfunctions. The best results in chemotherapy have been achieved for acute or recent chronic infections, with a lower rate of parasitological cure among more established chronic infections ([@B46], [@B02], [@B07]). Other studies have demonstrated that etiological treatment leads to a significant reduction in the development of electrocardiographic alterations, a slower clinical progression and the prevention of severe chronic cardiopathy ([@B40], [@B44], [@B42], [@B47], [@B14]). The indication of etiological treatment during the chronic phase of Chagas disease is controversial, as demonstrated by the operational difficulties with the post-treatment follow-up of chronic Chagas disease patients and the diversity of criteria and methodologies used in evaluating therapeutic efficacy ([@B13], [@B12]). From a serological, molecular and parasitological standpoint, the cure rates are highly variable when treatment is administered during the chronic phase of infection and the cure rates are dependent on the infection time and the time elapsed after the treatment evaluation ([@B13], [@B25], [@B31]). Higher cure rates have been observed in patients treated in the early chronic phase compared to the later chronic phase ([@B02], [@B43]).

Currently, the Brazilian Consensus in Chagas Disease recommends etiological treatment for all patients during the acute and early chronic disease phases ([@B34]). A larger, clinical, multicentre, randomised study called BENEFIT is in progress to evaluate the benefits of treatment on the clinical progression of chronic Chagas heart disease ([@B31]). Another large study, TRAENA, is being conducted in Argentina to evaluate whether treatment with benznidazole can modify the natural evolution of chronic Chagas disease in adult patients. In addition, controversies remain regarding the benefits of Chagas disease chemotherapy and parasitological cure interpretations after etiological treatment because of the genetic differences in parasites, time of infection, treatment scheme, time of follow-up, methodologies used and cure criteria ([@B13]).

The main goal of this study was to compare the laboratory {i.e., conventional serology, haemoculture and polymerase chain reaction (PCR)} and clinical {i.e., anamnesis, physical examination, electrocardiogram (ECG) and X-ray} progression of individuals from a known endemic area of Brazil who had been diagnosed with Chagas disease 13 years earlier.

PATIENTS, MATERIALS AND METHODS
===============================

*Study design* - This retrospective study used a case-control with a sample selection for the convenience of individuals who had received laboratory and clinical diagnoses of chronic Chagas disease 13 years prior. One patient group (n = 29) was treated with benznidazole and the other group (n = 29) was untreated (control group). The treated and untreated patients were matched with respect to the clinical form of Chagas disease, gender, age and geographical locality. Before the intervention, 46 patients presented with the indeterminate clinical form of the disease, 10 were classified as having the discrete cardiac form and two had the digestive form (megaesophagus group I) according to the OMS/OPAS (1974) classification. All laboratory and clinical data obtained at the beginning of this study and 13 years later from both groups were compared and the current clinical form determined following the same criteria used at baseline (OMS/OPAS 1974).

*Patients* - A group of 58 patients (20 males and 38 females) born and living in the municipality of Berilo, Jequitinhonha Valley, state of Minas Gerais (MG), Brazil, a Chagas disease vector-controlled area, was studied. *T. cruzi* infection was diagnosed in all patients in 1997 using conventional serological tests, including indirect immunofluorescence and ELISA. At that time, all patients were also clinically evaluated by anamnesis, physical examination, ECG and thorax X-ray using the [@B35] criteria, according to [@B33]. Of these patients, 29 (10 males and 19 females), aged six-37 years at the time of diagnosis, were etiologically treated with benznidazole (5 mg/kg/60 days). The majority (82.8%) of the patients were aged 22-37 years when treated. Thirteen years later, these patients were re-evaluated in parallel with 29 matched untreated patients (control group).

Before study inclusion, all patients or their legal guardians read and signed the consent term approved by the Ethical Committee for Human Research from René Rachou Research Centre, Oswaldo Cruz Foundation, Belo Horizonte, MG (process 007/2002).

*Laboratory evaluation - Conventional serological tests* - The serological evaluation was performed using sera samples obtained before and 13 years after the intervention. In-house ELISA, recombinant ELISA (rec-ELISA) and indirect haemagglutination (IHA) were used to evaluate only the sera collected 13 years after the intervention. Positive and negative control sera were run in parallel. The serum samples from the treated patients (collected before and after the treatment) were stored at the Chagas Disease Laboratory, Federal University of Ouro Preto, MG and matched with the serum samples from the untreated patients (control group); the samples were collected and examined in parallel.

An \"in-house\" ELISA was performed based on a modification of the [@B48] method, with 4.5 µg/mL of antigen obtained from *T. cruzi* Y strain, a serum dilution of 1:80 and peroxidase-anti-human IgG conjugate at a dilution of 1:7,500. The cut-off value calculated for each plate was the mean absorbance of 10 negative control serum samples plus two standard deviations ([@B38]).

The Chagatest-Wienner rec-ELISA kit was used (ELISA recombinant v.3.0; Wienner Laboratorios, Rosario, Argentina) and sera were processed according to the manufacturer\'s instructions. Positive and negative control sera were included in parallel and the cut-off was the mean absorbance of three negative control sera plus 0.3 optical densities (OD).

For the IHA assay, the Hemacruzi^(r)^ (bioMérieux, Brazil) kit was used according to the manufacturer\'s instructions.

*Parasitological and molecular methods* - These methods were used only during the final patient evaluation performed in 2010. One blood sample was collected from each patient. A portion of the volume was used for the haemoculture and the other portion was used for the PCR.

For haemoculture, the [@B10] methodology was used. Briefly, 30 mL of heparinised venous blood was centrifuged at 3,000 rpm for 10 min and the plasma was discarded. The pellet was resuspended in 15 mL of liver infusion tryptose (LIT) medium and centrifuged under the same conditions. After removing the supernatant, the pellet was resuspended in 15 mL of LIT, distributed into three tubes, maintained at 28ºC, homogenised every 48 h and examined at regular 30-day intervals for 120 days.

For the PCR, a modified methodology based on [@B24] was used. Blood samples (5 mL) were collected in an equal volume of 6 M guanidine-HCl and 0.2 M EDTA, pH 8.0, as described by [@B03]. The samples were kept at room temperature (RT) for seven days and then boiled in water for 10 min to cleave the DNA ([@B05]) before being stored at RT until processing. An aliquot of 200 µL of the lysate was subjected to DNA extraction with the Wizard^(r)^ Genomic DNA Purification kit (Promega, Cat A1125 Lot 262870). PCR amplifications were conducted in a 9 µL mixture containing Tris-HCl 10 mM (pH 9.0), 0.1% Triton X-100 (Invitrogen São Paulo, SP, Brazil), 75 mM KCl (Invitrogen São Paulo), 3.5 mM MgCl~2~ (Invitrogen São Paulo), 0.2 mM of each deoxynucleotide (dATP, dCTP, dGTP, dTTP; Sigma, St*.* Louis, MO, EUA), 0.5 U of Platinum *Taq* DNA polymerase (Invitrogen São Paulo) and 10 pmol of each oligonucleotide primer {121(AAATAATGTACGGGTGAGATGCATGA) and 122(GGTTCGATTGGGGTTGGTGTAATATA)}. Two microlitres of the blood DNA sample was added to the reaction mixture. After an initial denaturation step of 5 min at 94ºC, 35 cycles of amplification were performed in a thermal cycler (Biocycler MJ96G), each cycle consisted of 1 min at 95ºC for DNA denaturation, 1 min at 65ºC for primer annealing and 1 min at 72ºC for primer extension, followed by a final extension step of 10 min at 72ºC. Amplified DNA was visualised in silver-stained 6% polyacrylamide gels (Santos et al. 1993). All samples were processed in duplicate. Positive, negative and reagent controls were processed in parallel. Negative results were re-evaluated with primers for the human beta-globin gene PCO3 (ACACAAACTGTGTTCACTAGC) and PCO4 (CAACTTCATCCACGTTCACC) as an amplification control for the reaction.

*Clinical evaluation* - The final clinical evaluation (in 2010) and final clinical classification of all patients were performed by three physicians, who followed the same criteria used before treatment, as recommended by [@B35], including anamnesis, physical examination, ECG and thorax X-ray. Data from treated and untreated patients in 2010 were compared with the original data from each patient in 1997 obtained by Montoya (1998). The clinical progression of the disease was calculated by dividing the number of patients who evolved clinically (e.g., anamnesis, ECG and thorax X-ray alterations) by the total number of patients.

*Statistical analysis* - Comparative analyses of the absorbance (OD) obtained by conventional ELISA during the two assessments (before and 13 years after etiological treatment) and for the comparative analysis of clinical forms were performed using the non-parametric Wilcoxon test ([Figs 1](#f01){ref-type="fig"}, [2](#f02){ref-type="fig"}). Fisher\'s exact test was used to compare the proportion of positive haemoculture results, PCR and clinical progressions between the treated and untreated patients ([Figs 3](#f03){ref-type="fig"}, [4](#f04){ref-type="fig"}). The results were considered significant when p \< 0.05.

Fig. 1:anti- *Trypanosoma cruzi* IgG reactivity (ELISA) in serum samples from treated and untreated Chagas disease patients (CH) at the beginning of treatment (1997) and 13 years later (2010) (A) and clinically categorised as having the indeterminate (B) or cardiac/digestive (C) form of the disease. CHt: Chagas disease treated patients; CHnt: Chagas disease not treated patients. Asterisks mean significant differences (p \< 0.05).

Fig. 2:optical density (OD) of serum samples from patients infected with *Trypanosoma cruzi* in the treated and untreated groups at the beginning of the study (1997) and 13 years after intervention (2010).

Fig. 3:percentage of positivity of the parasitological method (haemoculture) and molecular test \[polymerase chain reaction (PCR)\] between patients infected by *Trypanosoma cruzi* treated (CHt) and untreated (CHnt) after 13 years of follow-up. Asterisks mean significant differences (p \< 0.05).

Fig. 4:clinical progression among Chagas disease patients treated (CHt) and untreated (CHnt) infected with *Trypanosoma cruzi* after 13 years of follow-up and grouped by the indeterminate (IND) treated (INDt), IND untreated (INDnt), and cardiac (CARD)/digestive (DIG) forms of the disease (DIGnt: DIG untreated; DIGt: DIG treated) based on clinical scores at the beginning of the study. Asterisks mean significant differences (p \< 0.05).

RESULTS
=======

In this study, the laboratory and clinical data from two matched Chagas patient groups (treated and untreated) were obtained before intervention (treatment) in 1997 and 13 years later (2010) and compared.

*Laboratory evaluation* - *Serology* - All patients displayed positive results in conventional serological tests. A more detailed analysis of the stored sera using an \"in house\" ELISA assay revealed that before treatment (1997), the median absorbance values displayed no significant differences between the treated and untreated groups (p \> 0.05). After 13 years (in 2010), the serological evaluation revealed a lower absorbance reading in the sera of patients of the treated group compared with the untreated group (p \< 0.05) ([Fig. 1A](#f01){ref-type="fig"}).

When the patients were grouped by the clinical form of the disease exhibited before treatment, a lower absorbance in the treated group with the indeterminate form of the disease was observed compared with the untreated group (p \< 0.05) ([Fig. 1B](#f01){ref-type="fig"}). This absorbance difference was not observed ([Fig. 1C](#f01){ref-type="fig"}) in the patients who had cardiac or digestive alterations before treatment.

The comparison of the absorbance of sera samples collected in the beginning of the study (1997) and 13 years after intervention (2010) revealed that in the treated group, the majority of patients presented stabilisation or lower serological reactivity (p \> 0.05) ([Fig. 2A](#f02){ref-type="fig"}), whereas in the untreated group, the majority of the patients exhibited increased reactivity (p \< 0.0001) ([Fig. 2B](#f02){ref-type="fig"}).

*Parasitological and molecular evaluation* - Haemoculture revealed positive results in 6.9% and 27.6% of the treated and untreated patients, respectively, and these differences were significantly different ([Fig. 3](#f03){ref-type="fig"}). PCR produced positive results in 44.8% and 13.8% of the treated and untreated patients, respectively, and these differences were also significant ([Fig. 3](#f03){ref-type="fig"}).

*Clinical evaluation* - Table shows the age, gender and clinical form of each patient etiologically treated before and 13 years after the intervention.

Thirteen years after the intervention (treatment), clinical evaluation revealed that 27.6% of the treated patients and 65.5% of the untreated patients presented with disease progression (p \< 0.05) ([Fig. 4](#f04){ref-type="fig"}). When the patients were grouped according to the clinical form observed before treatment, the patients that received treatment during the indeterminate clinical form of the disease displayed less progression/evolution of the disease (17.4%) compared with untreated patients (56.5%) ([Fig. 4](#f04){ref-type="fig"}). In the untreated group, all patients who exhibited cardiac or digestive alterations progressed clinically throughout this study. The data revealed a lower percentage of annual clinical progression in the treated group (2.12%) compared with the untreated group (5.03%). This result was verified in the comparison of the annual index of clinical progression observed in the treated (1.33%) and untreated (4.34%) patients who presented with the indeterminate clinical form of the disease in the beginning of the study. However, this difference was not observed in the group of patients with cardiac and digestive alterations.

DISCUSSION
==========

At the individual level, the treatment goals for *T. cruzi* infection are eliminating the parasite, decreasing the probability of clinical progression of the disease and indirectly affect *T. cruzi* transmission using vectorial and non-vectorial mechanisms of infection ([@B41]).

Several randomised studies have suggested that the etiological treatment of Chagas disease leads to negative results in serological tests and/or the prevention of electrocardiographic and clinical changes related to disease progression ([@B30], [@B32], [@B46], [@B47], [@B19], [@B20], [@B17], [@B14]). However, other studies are contradictory and indicate that when treatment is administered during the chronic phase of the disease, the parasite is not eliminated, the progress of the disease is not interrupted; therefore, the complications of the infection are not prevented ([@B26], [@B01], [@B27], [@B04], [@B29]). Controversies still exist regarding the real effects of the drugs used in human treatment on the clinical progression of Chagas disease, particularly during the chronic phase of the infection ([@B30], [@B04], [@B29]). These contradictions are most likely caused by the use of different treatment regimens and/or post-treatment evaluation protocols ([@B12]). Consequently, despite the evidence that trypanocidal therapy may positively impact the clinical course of the disease in chronically infected patients ([@B42]), there is neither a consensus nor sufficient data to support the routine use of the etiological treatment of Chagas disease at this stage of infection ([@B31]).

In this work, we comparatively evaluated the clinical and laboratory progression of etiologically treated and untreated Chagas disease patients after 13 years of follow-up.

All treated and untreated patients were reactive in the conventional serology (ELISA, IHA and rec-ELISA) 13 years after the intervention. A more detailed assessment using ELISA indicated a lower absorbance reading in the sera of treated patients compared with untreated patients. The lower absorbance rate was verified in the patients who were treated during the indeterminate form of the disease compared with the patients who displayed cardiac and/or digestive alterations before the treatment. After the treatment, decreased serological titres have been observed in several studies ([@B02], [@B43], [@B16], [@B18], [@B45]), but the decay occurs slowly, particularly among patients treated during the chronic phase of the disease; this result justifies the need for several years of follow-up to verify the parasitological cure. [@B43] evaluated children treated with benznidazole during the indeterminate form of the disease during four years of follow-up and observed a significant decrease in serological titres in the treated patients, whereas no changes were observed among the patients who received placebos. This result may be because the patients were young (\< 12 years), in which case the decrease of specific antibodies is more precocious.

Haemoculture is an important parameter for post-treatment evaluation because when positive the therapeutic failure is evident ([@B13]). This technique revealed therapeutic failure in two/29 (6.9%) of the patients in the treated group and was positive in eight/29 (27.6%) of the patients in the untreated group. Haemoculture is useful for monitoring parasitological cures, but negative results must be carefully analysed because they do not necessarily indicate a cure because of low parasitaemia, which is characteristic of chronic patients (particularly treated patients) because of the intermittent nature of the parasitaemia, which can explain the low sensitivity of this parasitological method ([@B10], [@B28], [@B11], [@B23]). Our data corroborated the work of [@B08] who evaluated treated and untreated patients and observed a high prevalence of positive haemoculture results in an untreated patient group compared with a treated group.

PCR revealed positivity in 44.8% of the treated patients and 13.8% of the untreated group. More studies are necessary to verify the results obtained by this methodology in the context of the follow-up of treated patients compared with other laboratorial methods employed in humans and experimental models for the evaluation of treatment efficacy. Although the PCR technique is of higher sensitivity than haemoculture, these PCR results can be also attributed to the intermittent nature of the parasitaemia in chronic patients. Moreover, the blood samples examined in both methods (haemoculture and PCR) were not the same (Galvão et al*.* 2003, Britto 2009), but collected at the same time in different tubes. It is important to highlights that the global serological results of the treated patients did not show parasitological cure, according to the classic cure criteria ([@B49]). This is not surprising because previous evaluation by PCR of these same patients (de Lana et al. 2009) four years before revealed also high percentage of positivity (85.2%). However, it is important to highlight that this percentage was obtained two blood samples: the first with 64% and the second 54% of positivity. In the present work, were only one blood sample was examined. Moreover, the reaction controls show the reliability of the technique {in both phases, DNA extraction (amplification of human beta-globin gene) and PCR reaction} and eliminate the possibility of risk of contamination by k-DNA aerosol. Thus, some of the patients still have the infection or at least kDNA of *T. cruzi* in their bloodstreams. The results obtained may be also explained due the intermittent character of the parasitaemia and because only one sample of each patient was evaluated.

After 13 years of follow-up, the clinical evaluation revealed that 27.6% of the treated patients showed clinical progression and 65.5% of patients in the untreated group did as well. These results indicate that etiological treatment significantly delays the clinical progression of the disease, even in cases in which a parasitological cure was not yet observed. These data confirm the reports of several other authors that comparatively evaluated groups of treated and untreated patients ([@B46], [@B17], [@B16], [@B20]). [@B47]evaluated groups of patients with *T. cruzi* infection who were untreated or treated with benznidazole and revealed that the treated patients showed less disease progression (4% vs. 14%) or developed fewer ECG abnormalities (5% vs. 16%) compared with untreated patients. These authors also demonstrated that treatment intervention was associated with reduced clinical progression of Chagas disease and a better prognosis. [@B16] evaluated 111 patients with Chagas disease (54 treated and 57 untreated) and observed a 37% seroconversion in the treated group and a 27.8% decrease in serological titres. Moreover, the patients in the untreated group exhibited stable serological titres. The percentage of clinical progression was 3.7% in the treated group and 15.8% in the untreated group, which suggests that treatment induces a protective effect against the clinical progression of Chagas disease. This observation was more evident in the patients who had the indeterminate form of the disease at the beginning of the study. In this group, the clinical progression was observed in 17.4% of the treated patients and 56.5% of the untreated patients. These results indicate that treatment may prevent disease progression and reveals a better prognosis for patients treated during the indeterminate form of the disease, which confirms the findings of other studies (Gallerano & Sosa 2000, Viotti et al. 2006, de Lana et al. 2009). However, the number of treated patients who displayed cardiac and digestive alterations prior to treatment was low to allow a definitive interpretation regarding the prognosis of the disease following etiological treatment.

###### Distribution of the patients etiological treated according to age when treated, gender and clinical form before and 13 years after treatment 

  Patients   Age   Sex   Clinical form   
  ---------- ----- ----- --------------- -------------
  1^*a*^     37    F     IF              CF mild
  2^*a*^     33    M     IF              CF mild
  3^*a*^     6     F     IF              CF mild
  4^*a*^     34    F     IF              CF mild
  5          10    M     IF              IF
  6          23    F     IF              IF
  7          25    M     IF              IF
  8          27    M     IF              IF
  9          30    F     IF              IF
  10         25    F     IF              IF
  11         28    M     IF              IF
  12         28    M     IF              IF
  13         31    M     IF              IF
  14         34    F     IF              IF
  15         30    F     IF              IF
  16         29    F     IF              IF
  17         29    F     IF              IF
  18         16    F     IF              IF
  19         25    F     IF              IF
  20         33    F     IF              IF
  21         31    M     IF              IF
  22         37    F     IF              IF
  23         14    F     IF              IF
  24         23    F     CF mild         CF mild
  25         30    F     CF mild         CF mild
  26^*a*^    16    M     CF mild         CF moderate
  27^*a*^    34    M     CF mild         CF moderate
  28^*a*^    22    F     CF mild         CF severe
  29^*a*^    26    F     DF (1º)         DF (3º)

*a* : patients that showed clinical progression after 13 years; CF: cardiac form; DF: digestive form; F: female; IF: indeterminate form; M: male.

This retrospective, comparative study matched treated and untreated Chagas patients by the clinical form of the disease before intervention (treatment) and by gender, age and geographical locality using laboratory and clinical evaluations. Even considering the low number of patients overall, this study revealed that the etiological treatment with benznidazole may benefit patients during the clinical progression of the disease and provide a better prognosis, particularly when the treatment is administered to patients with the indeterminate form of the disease.
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